Merck Acquires Modifi Biosciences for $30 Million
On October 23, Merck & Co., Inc., known as MSD outside the United States and Canada, announced that it acquired Modifi Biosciences for $30 million upfront. Modifi Biosciences has developed a novel class of small molecules that target cancer cells lacking expression of a key DNA repair protein called O6-methylguanine methyltransferase. It is a Yale University spinout company that was formed in 2021. Merck is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company is focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines and animal health products.... Read More »
Valerio Therapeutics Acquires Emglev Therapeutics
On September 30, Valerio Therapeutics, a Paris-based, clinical-stage biotechnology company, announced its acquisition of Emglev Therapeutics. Founded in 2023, Emglev is a biotechnology company that was established as a spin-off of Institut Curie and aims to develop immunotherapies to address unmet medical needs in oncology. It is a single-domain antibody-based therapeutics company. It is headquartered in Paris, France. Valerio Therapeutics is focused on developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response. The company is focused on bringing early-stage... Read More »
Molecular Designs Acquires Lamda Biotech
On September 25, Molecular Designs announced that it entered into an agreement to acquire Lamda Biotech. Lamda Biotech is a specialized provider of research products for application in molecular biology, functional genomics, proteomics and gene therapy. For more than 20 years, Lamda Biotech has been highly regarded for its offering of cutting-edge PCR products, RT-PCR reagents, RT-qPCR kits, Direct-PCR genotyping kits, DNA ladders, SafeStain and other protein and cell biology products. Molecular Designs is a team of doctors and scientists working to advance molecular diagnostics. It offers numerous multiplex PCR-based panels produced under GMP and ISO 13485:2016 quality... Read More »
Rafael Holdings Merges With Cyclo Therapeutics
Rafael Holdings, Inc. and Cyclo Therapeutics, Inc. announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. The companies are building on a year-long history of strategic collaboration and investment. The merger involves Rafael Holdings issuing Class B common stock to Cyclo Therapeutics shareholders, valuing Cyclo shares at $0.95 each. In addition, the cash value will take into account the funding of Cyclo’s operations by Rafael with convertible notes through closing. Cyclo Therapeutics is a clinical-stage biotechnology company that focuses on the use... Read More »
Crown Laboratories Merges with Revance Therapeutics
Crown Laboratories, Inc., a portfolio company of New York City-based private equity firm Hildred Capital Partners LLC, announced that it entered into an agreement to acquire Revance Therapeutics, Inc. Crown will commence a tender offer to acquire all outstanding shares of Revance’s common stock for $6.66 per share in cash, representing a total enterprise value of $924 million. The purchase price represents a premium of 89% over Revance’s closing market price on August 9, 2024, and a 111% premium to Revance’s 60-day volume-weighted average price. Revance Therapeutics, Inc. is a biotechnology company based in Nashville, Tennessee. Revance’s... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
